Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$7.39
+1.7%
$7.40
$6.96
$16.47
N/A1.131.92 million shs1.41 million shs
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$44.86
+0.4%
$51.03
$44.34
$69.10
$90.92B0.3915.97 million shs21.28 million shs
CSL Limited stock logo
CSLLY
CSL
$89.60
-0.6%
$91.98
$71.51
$105.11
$86.60B0.7335,357 shs26,288 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$733.51
+1.2%
$761.79
$380.77
$800.78
$696.95B0.343.02 million shs2.00 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
+0.14%+3.27%-1.36%-17.29%-55.91%
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-8.56%-7.49%-14.98%-10.10%-34.31%
CSL Limited stock logo
CSLLY
CSL
+0.07%+3.73%-2.33%-6.76%-10.23%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.00%-2.83%-6.49%+13.40%+92.65%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/AN/AN/AN/AN/AN/AN/AN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9509 of 5 stars
4.14.03.34.02.31.71.9
CSL Limited stock logo
CSLLY
CSL
1.2683 of 5 stars
0.05.01.70.01.70.01.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8133 of 5 stars
2.43.02.54.03.02.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.89
ReduceN/AN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0033.75% Upside
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.74% Downside

Current Analyst Ratings

Latest BMY, CSLLY, LLY, and BAYRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$51.55BN/A$3.91 per share1.89$10.44 per shareN/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.01B2.02$11.44 per share3.92$14.49 per share3.10
CSL Limited stock logo
CSLLY
CSL
$13.31B6.51$3.12 per share28.74$18.48 per share4.85
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.42$7.64 per share96.01$11.44 per share64.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-$3.18B-$0.82N/A5.06N/A-6.31%17.27%5.20%N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B$3.8611.626.361.4717.83%50.95%16.67%7/25/2024 (Estimated)
CSL Limited stock logo
CSLLY
CSL
$2.19BN/A0.0024.96N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.4739.651.6015.36%51.22%9.94%4/30/2024 (Confirmed)

Latest BMY, CSLLY, LLY, and BAYRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
3/5/202412/31/2023
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.38$0.50+$0.12$0.63N/A$12.77 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.456.09%N/AN/A N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.35%+8.20%62.18%N/A
CSL Limited stock logo
CSLLY
CSL
$1.091.22%N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years

Latest BMY, CSLLY, LLY, and BAYRY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/3/2024
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.01914/29/20244/30/20245/13/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.15
1.27
0.80
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
CSL Limited stock logo
CSLLY
CSL
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
CSL Limited stock logo
CSLLY
CSL
0.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
CSL Limited stock logo
CSLLY
CSL
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
99,723N/AN/ANot Optionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
CSL Limited stock logo
CSLLY
CSL
32,000966.51 millionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

BMY, CSLLY, LLY, and BAYRY Headlines

SourceHeadline
A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1
forbes.com - April 26 at 9:58 PM
Bryn Mawr Capital Management LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)Bryn Mawr Capital Management LLC Increases Holdings in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 26 at 9:27 PM
Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.5%Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.5%
marketbeat.com - April 26 at 5:58 PM
What You Need To Know Ahead of Eli Lillys Earnings Report TuesdayWhat You Need To Know Ahead of Eli Lilly's Earnings Report Tuesday
investopedia.com - April 26 at 5:05 PM
Eli Lilly and Company (NYSE:LLY) Given Average Recommendation of "Moderate Buy" by AnalystsEli Lilly and Company (NYSE:LLY) Given Average Recommendation of "Moderate Buy" by Analysts
americanbankingnews.com - April 26 at 1:22 AM
Stanley Laman Group Ltd. Sells 1,558 Shares of Eli Lilly and Company (NYSE:LLY)Stanley Laman Group Ltd. Sells 1,558 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 25 at 11:45 PM
Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.3%Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.3%
marketbeat.com - April 25 at 6:18 PM
As Eli Lillys Insulin Pricing Settlement Unravels, Lawyers Vow to Push AheadAs Eli Lilly's Insulin Pricing Settlement Unravels, Lawyers Vow to Push Ahead
law.com - April 25 at 5:06 PM
20 Fastest Growing Health Tech Companies in the World20 Fastest Growing Health Tech Companies in the World
finance.yahoo.com - April 25 at 12:06 PM
Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 25 at 10:20 AM
Dont Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy ListDon't Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
investorplace.com - April 25 at 6:04 AM
Sycomore Asset Management Buys 3,462 Shares of Eli Lilly and Company (NYSE:LLY)Sycomore Asset Management Buys 3,462 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 24 at 10:27 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 1.6% Eli Lilly and Company (NYSE:LLY) Shares Down 1.6%
marketbeat.com - April 24 at 4:21 PM
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best GuessesWhich Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
investorplace.com - April 24 at 2:51 PM
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus PharmaEli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
msn.com - April 24 at 2:04 PM
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
zacks.com - April 24 at 1:06 PM
4 Large Drug Stocks to Hold on to Amid Industry Challenges4 Large Drug Stocks to Hold on to Amid Industry Challenges
zacks.com - April 24 at 11:11 AM
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
zacks.com - April 24 at 10:26 AM
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to KnowInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
zacks.com - April 24 at 10:06 AM
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
morningstar.com - April 24 at 9:04 AM
Meet Eli Lillys Secret Weapon in the Billion-Dollar Weight Loss Drug MarketMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight Loss Drug Market
fool.com - April 24 at 9:04 AM
Meet Eli Lillys Secret Weapon in the Billion-Dollar Weight-Loss Drug MarketMeet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
fool.com - April 24 at 6:40 AM
Eli Lilly and Company (NYSE:LLY) Shares Sold by Yousif Capital Management LLCEli Lilly and Company (NYSE:LLY) Shares Sold by Yousif Capital Management LLC
marketbeat.com - April 23 at 9:37 PM
Lilly’s $3.7B manufacturing campus in Boone County starting to take shapeLilly’s $3.7B manufacturing campus in Boone County starting to take shape
ibj.com - April 23 at 8:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bayer Aktiengesellschaft logo

Bayer Aktiengesellschaft

OTCMKTS:BAYRY
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
CSL logo

CSL

OTCMKTS:CSLLY
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.